Skip to main content
. 2016 Nov 17;5:48. doi: 10.1186/s13756-016-0145-0

Table 2.

Comparison of antimicrobial therapies and treatment outcomes between CRKP-BSI and CSKP-BSI patients

Treatment and outcomes Total (n = 114) CRKP (n = 33) CSKP (n = 81) p-value
Appropriate empirical antimicrobial therapy 78(68.4) 9(27.3) 69(85.2) <0.001
LOS after BSI onset,Days, median (IQR) 18.5(9–31) 24(9.5–51) 15(8.5–28) 0.066
Total LOS,days, median (IQR) 31.5(19.75–62.75) 50(28–83) 24(16.5–51) 0.001
Mortality rate
 Crude 28-day mortality n(%) 26(22.8) 11(33.3) 15(18.5) 0.087
 Crude in-hospital mortality n(%) 30(26.3) 14(42.4) 16(19.8) 0.013
 Attributable 28-day mortality n(%) 24(21.1) 11(33.3) 13(16.0) 0.04
 Attributable in-hospital mortality n(%) 28(24.6) 14(42.4) 14(24.6) 0.005

IQR interquartile range, BSI bloodstream infection, CRKP carbapenem-resistant Klebsiella pneumoniae, CSKP carbapenem-sensitive Klebsiella pneumoniae, LOS length of stay